4a. Commentaries

  1. Dan J. Stein MD, PhD4,5,
  2. Matthew J. Friedman MD6,7 and
  3. Carlos Blanco MD, PhD8
  1. Marcelo F. Mello1,
  2. Michael Van Ameringen2,
  3. Beth Patterson2 and
  4. Murray B. Stein3

Published Online: 15 JUL 2011

DOI: 10.1002/9781119998471.ch4a

Post-Traumatic Stress Disorder

Post-Traumatic Stress Disorder

How to Cite

Mello, M. F., Van Ameringen, M., Patterson, B. and Stein, M. B. (2011) Commentaries, in Post-Traumatic Stress Disorder (eds D. J. Stein, M. J. Friedman and C. Blanco), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9781119998471.ch4a

Editor Information

  1. 4

    Department of Psychiatry, University of Cape Town, Cape Town, South Africa

  2. 5

    Mount Sinai School of Medicine, New York, NY, USA

  3. 6

    Department of Psychiatry and of Pharmacology & Toxicology, Dartmouth Medical School, USA

  4. 7

    National Center for Posttraumatic Stress Disorder, US Department of Veterans Affairs, Hanover, NH, USA

  5. 8

    Department of Psychiatry, Columbia University, New York, NY, USA

Author Information

  1. 1

    Department of Psychiatry, Universidade Federal de São Paulo, São Paulo, Brazil

  2. 2

    Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada

  3. 3

    Department of Psychiatry and Family and Preventive Medicine, University of California San Diego, CA, USA

Publication History

  1. Published Online: 15 JUL 2011
  2. Published Print: 29 JUL 2011

Book Series:

  1. World Psychiatric Association Evidence and Experience in Psychiatry Series

Book Series Editors:

  1. Helen Herrman

Series Editor Information

  1. WPA Secretary for Publications, University of Melbourne, Australia

ISBN Information

Print ISBN: 9780470688977

Online ISBN: 9781119998471



  • pharmacological treatment of trauma - critical view;
  • Stein and Ipser's ‘Pharmacotherapy of PTSD’ - contribution, to knowledge of PTSD treatment;
  • PTSD pharmacotherapy, shortcomings and future directions - theoretical positions;
  • key issues in using SSRIs - agent to choose, dose, treatment and relapse;
  • sexual traumas, large percentage - of civilian PTSD treatment study populations;
  • gains in pharmacological treatment of PTSD - efficacy of SSRIs, first-line treatments;
  • new PTSD pharmacotherapeutics - afterthought, in minds of psychotropic drug developers;
  • psychopharmacological clinician-researchers - rising to the challenge, new PTSD medicines


This chapter contains sections titled:

  • Critical View of the Pharmacological Treatment of Trauma

  • Shortcomings and Future Directions of the Pharmacotherapy of PTSD

  • Dire Need for New PTSD Pharmacotherapeutics